Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy

Documenti analoghi

• Structural modification of 2‐phenylquinoline‐4‐carboxylic acid containing SIRT3 inhibitors for the cancer differentiation therapy
  di: Yanmei Du, et al.
  Pubblicazione: (2024)
• EGFR degraders in non‐small‐cell lung cancer: Breakthrough and unresolved issue
  di: Jiayi Shen, et al.
  Pubblicazione: (2024)
• Design, synthesis, in silico molecular docking, and ADMET studies of quinoxaline‐isoxazole‐piperazine conjugates as EGFR‐targeting agents
  di: Mohammad Imtiyaz Ali, et al.
  Pubblicazione: (2024)
• Design, Docking, ADMET , Pass, Synthesis and Bio‐Evaluation of Novel 7‐ O ‐Substituted Chrysin‐Based VEGFR ‐2 Inhibitors
  di: Kalyani R. Thombre, et al.
  Pubblicazione: (2026)
• Design, synthesis, and evaluation of novel bistrifluoromethyl‐based hydrazones as dual inhibitors of acetylcholinesterase and carbonic anhydrase enzymes for Alzheimer's disease
  di: Efe Doğukan Dincel, et al.
  Pubblicazione: (2024)